Efficacy and safety evaluation of PSOX, DOF and SOX regimens as neoadjuvant chemotherapy for advanced gastric cancer

• Published in: Future oncology (London, England) Vol. 18; no. 40; pp. 4483 - 4492
• Main Authors: Yu, Pengjie, Zhu, Shengmao, Pu, Yongqiang, Cai, Baojia, Ma, Xiaoming, Zhang, Chengwu
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.12.2022
• Subjects: advanced gastric cancer; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Docetaxel - adverse effects; efficacy; Humans; neoadjuvant chemotherapy; Neoadjuvant Therapy; Oxaliplatin - adverse effects; Paclitaxel - adverse effects; PSOX; Retrospective Studies; safety; Stomach Neoplasms - drug therapy; Stomach Neoplasms - etiology; neoadjuvant chemotherapy; PSOX; advanced gastric cancer; safety; efficacy
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2022-0337

To explore the efficacy and safety of paclitaxel+oxaliplatin+S-1 (PSOX), docetaxel+oxaliplatin+fluorouracil (DOF) and oxaliplatin+S-1 (SOX) regimens as neoadjuvant chemotherapy for advanced gastric cancer (GC). A retrospective analysis was used in 306 patients with GC who underwent neoadjuvant chemotherapy, consisting of 102 from the PSOX group, 100 from the DOF group and 104 from the SOX group. The total effective rates and disease control rates for the PSOX, DOF and SOX groups were 31.4, 18 and 16.3% and 96.1, 94 and 92.3%, respectively. The highest total effective rate and disease control rate were found in the PSOX groups. Moreover, no difference among the PSOX, DOF and SOX groups on the incidence of adverse events was observed (p > 0.05). The PSOX regimen is an alternative neoadjuvant chemotherapy regimen for GC patients.